BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1489283)

  • 1. Electron microscopic observation of killer cells induced by mixed culture of lymphocytes with autologous cancer cells and further culture with recombinant interleukin-2.
    Murakami H; Matsuoka H; Fukiage T; Samejima Y; Eura M; Ikawa T; Ishikawa T; Kanda T
    Auris Nasus Larynx; 1992; 19(3):175-88. PubMed ID: 1489283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
    Koyama S
    J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphofunctional characterization of lymphokine activated killer (LAK) cells in vitro.
    Nano R; Capelli E; Gerzeli G
    Boll Soc Ital Biol Sper; 1995; 71(7-8):181-7. PubMed ID: 8519494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.
    Roth AD; Dupuis S; Alberto P
    Clin Exp Immunol; 1995 Aug; 101(2):362-8. PubMed ID: 7648722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrastructural characteristics of lymphokine-activated killer cells of the rat in comparison with natural killer cells.
    Kaneda K; Nagamuta M; Kataoka M; Yamamoto H; Kishiye T; Wake K
    Arch Histol Cytol; 1991 May; 54(2):119-32. PubMed ID: 1873071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas.
    Tsukuda M; Mochimatsu I; Sakumoto M; Furukawa S; Yuyama S; Yanoma S; Kubota A
    Biotherapy; 1993; 6(2):155-61. PubMed ID: 8398575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological responses against an autologous human hepatocellular carcinoma cell line.
    Usuda S; Yoshizawa K; Yabu K; Kiyosawa K
    J Gastroenterol Hepatol; 1993; 8(6):517-23. PubMed ID: 8280838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight B-cell growth factor and recombinant interleukin-2 are together able to generate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Ragab AH
    Blood; 1989 Sep; 74(4):1355-9. PubMed ID: 2788465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
    Grimm EA; Wilson DJ
    Cell Immunol; 1985 Sep; 94(2):568-78. PubMed ID: 3928175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of human cytotoxic T lymphocytes against autologous solid tumors by autologous mixed lymphocyte tumor cell culture with T cell growth factor.
    Ichino Y; Ishikawa T
    Auris Nasus Larynx; 1985; 12 Suppl 2():S226-33. PubMed ID: 2942136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.